Solid tumors account for approximately 60% of all childhood malignancies. Over the last 40 years, despite multiple therapeutic approaches including surgery, chemotherapy, radiation, megatherapy and targeted therapy, metastatic and recurrent/ refractory pediatric solid tumors have a dismal prognosis. Novel therapeutic strategies are urgently required and represent an unmet need.
Immunotherapy has proven effective in pediatric hematological malignancies, but there remains much to be learned before we can harness the potential of immunotherapy in the treatment of solid tumors. The poor prognosis of pediatric solid tumors is in large part secondary to an immunosuppressive and resistant tumor microenvironment (TME). Identification of the mechanisms of TME resistance in pediatric solid tumors and exploration of novel approaches to targeting these resistant mechanisms will help overcome the hurdles in immunotherapy against pediatric solid tumors.
This Research Topic accepts Original Research, Systematic Review, Methods, Review and Mini-Review, Brief Research Report, Data Report. We welcome manuscripts focusing on, but not limited to, the following sub-topics:
• Identification of novel surface targets in pediatric solid tumors
• Identification of novel mechanisms of TME resistance in pediatric solid tumors
• Novel approaches to engineering immune cells to target pediatric solid tumors
• Rational combinations of immunotherapy against pediatric solid tumors
• Comprehensive review of the literature on advances in immunotherapy in pediatric solid tumors
Topic Editor Dr. Mitchell Cairo is a consultant for Jazz Pharmaceuticals, Omeros Pharmaceuticals, Servier Pharmaceuticals, Abbvie and Novartis Pharmaceuticals, whilst also on the Speakers Bureau for Jazz Pharmaceuticals, Servier Pharmaceuticals, Amgen, Inc., Sanofi and Sobi, and is on the Advisory Board for Astra Zeneca, and has received research funding from Celularity, Merck, Miltenyi Biotec, Servier, Omeros, Jazz and Janssen. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Solid tumors account for approximately 60% of all childhood malignancies. Over the last 40 years, despite multiple therapeutic approaches including surgery, chemotherapy, radiation, megatherapy and targeted therapy, metastatic and recurrent/ refractory pediatric solid tumors have a dismal prognosis. Novel therapeutic strategies are urgently required and represent an unmet need.
Immunotherapy has proven effective in pediatric hematological malignancies, but there remains much to be learned before we can harness the potential of immunotherapy in the treatment of solid tumors. The poor prognosis of pediatric solid tumors is in large part secondary to an immunosuppressive and resistant tumor microenvironment (TME). Identification of the mechanisms of TME resistance in pediatric solid tumors and exploration of novel approaches to targeting these resistant mechanisms will help overcome the hurdles in immunotherapy against pediatric solid tumors.
This Research Topic accepts Original Research, Systematic Review, Methods, Review and Mini-Review, Brief Research Report, Data Report. We welcome manuscripts focusing on, but not limited to, the following sub-topics:
• Identification of novel surface targets in pediatric solid tumors
• Identification of novel mechanisms of TME resistance in pediatric solid tumors
• Novel approaches to engineering immune cells to target pediatric solid tumors
• Rational combinations of immunotherapy against pediatric solid tumors
• Comprehensive review of the literature on advances in immunotherapy in pediatric solid tumors
Topic Editor Dr. Mitchell Cairo is a consultant for Jazz Pharmaceuticals, Omeros Pharmaceuticals, Servier Pharmaceuticals, Abbvie and Novartis Pharmaceuticals, whilst also on the Speakers Bureau for Jazz Pharmaceuticals, Servier Pharmaceuticals, Amgen, Inc., Sanofi and Sobi, and is on the Advisory Board for Astra Zeneca, and has received research funding from Celularity, Merck, Miltenyi Biotec, Servier, Omeros, Jazz and Janssen. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
